Results 171 to 180 of about 98,309 (302)

Primary central nervous system lymphoma and tumefactive demyelinating lesions in multiple sclerosis: a retrospective observational cohort study. [PDF]

Front Oncol
Chen Y, Shen L, Chen S, Zheng S, Xie J, Zheng S.   +5 more
europepmc   +1 more source

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, EarlyView.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review. [PDF]

Front Immunol
Aureli A, Lanzilli G, Boccadamo Pompili SV, Spagnoli GC, Sconocchia G, Caratelli S.   +5 more
europepmc   +1 more source

A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection

Alimentary Pharmacology &Therapeutics, EarlyView.
Cirrhosis patients with untreated HBV in Ethiopia exhibit a distinct immune profile marked by depletion of NK cells, B cells, and T cells, alongside an expanded CD38+HLA‐DR+ CD8 T‐cell population. ABSTRACT Background and Aims The immune cell phenotype of African patients living with chronic hepatitis B virus (HBV) infection is rarely described, despite
Julia MacLeod, Fikadu G. Gudissa, Asiya Jeylan, Nega Berhe, Hailemichael Desalegn, Lasse Rossvoll, Asgeir Johannessen, Niklas K. Björkström, Dag Henrik Reikvam, Annika Niehrs   +9 more
wiley   +1 more source

Spatial organization of the tumor immune microenvironment in LAR+ triple-negative breast cancer. [PDF]

Front Immunol
Lucchetti D, Di Leone A, Sabbatinelli G, Toma F, Antonio F, Cellini B, Colella F, Pazzaglia E, Parrillo C, Giacó L, Santoro A, Piermattei A, Colonna R, Franceschini G, Sgambato A.   +14 more
europepmc   +1 more source

Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacy. [PDF]

Immunity
Cheng BY, Centeio RM, Chiu DK, Kiyohara CL, Herzog E, Dahan R, Thomas WE, Wang TT.   +7 more
europepmc   +1 more source

Induced pluripotent stem cell-derived natural killer cells: poised for the clinic as an off-the-shelf allogeneic cell therapy. [PDF]

Transl Cancer Res
Xiong T, Yu J.
europepmc   +1 more source

Canine CD20 gene

Canine CD20 gene
The human CD20 antigen, a 35 kDa cell surface nonglycosylated hydrophobic phoshpoprotein is expressed consistently on almost all human B-cells, and its monoclonal antibody is used for the therapy on human B-cell lymphoma. In the present study, canine CD20 gene was cloned and sequenced, and the expression of CD20 mRNA was investigated in canine ...
openaire  

Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

British Journal of Haematology, EarlyView.
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco, Dario Leotta, Alessandro Allegra, Daniele Caracciolo, Laura Caruso, Annalisa Chiarenza, Vittorio Del Fabro, Valentina Di Martina, Amalia Figuera, Paolo Fabio Fiumara, Massimo Gentile, Vanessa Innao, Salvatrice Mancuso, Enrica Antonia Martino, Antonio Mosca, Giovanna Motta, Francesca Pedalino, Marco Rossi, Fabio Stagno, Giorgio Tona, Francesco Di Raimondo, Giuseppe Alberto Palumbo   +21 more
wiley   +1 more source

Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma. [PDF]

Cells
Maher N, Al Deeban B, Diop NM, Assaf J, Moia R, Mouhssine S, Gaidano G.   +6 more
europepmc   +1 more source